BioNTech SE ADR's income statement, balance sheet and cash flow statement as filed with the SEC (10-K and 10-Q), with the latest fiscal years and quarters. In its latest fiscal year (Dec 31, 2025 · FY), BioNTech SE ADR reported revenue of $2.9B (+4.3% year on year).
| Line item | Dec 31, 2025 · FY | Dec 31, 2024 · FY | Dec 31, 2023 · FY | Dec 31, 2022 · FY |
|---|---|---|---|---|
| Revenues | $2.9B | $2.8B | $3.8B | $17.3B |
| Cost of sales | ($641.8M) | ($541.3M) | ($599.8M) | ($3.0B) |
| Research and development expenses | ($2.1B) | ($2.3B) | ($1.8B) | ($1.5B) |
| Sales and marketing expenses | ($110.0M) | ($67.9M) | ($62.7M) | ($59.5M) |
| General and administrative expenses | ($514.4M) | ($531.1M) | ($495.0M) | ($484.7M) |
| Other operating expenses | ($1.1B) | ($811.5M) | ($293.0M) | ($407.0M) |
| Other operating income | $184.6M | $140.6M | $105.0M | $815.3M |
| Operating profit / (loss) | ($1.4B) | ($1.3B) | $690.4M | $12.6B |
| Finance income | $423.9M | $664.0M | $519.6M | $330.3M |
| Finance expenses | ($69.8M) | ($27.4M) | ($23.9M) | ($18.9M) |
| Profit / (Loss) before tax | ($1.1B) | ($677.7M) | $1.2B | $13.0B |
| Income taxes | ($85.3M) | $12.4M | ($255.8M) | ($3.5B) |
| Profit attributable to ordinary equity holders of the parent for basic earnings | ($1.1B) | — | — | — |
| Net profit / (loss) | ($1.1B) | ($665.3M) | $930.3M | $9.4B |
| Basic earnings for the period per share (in euros per share) | -$4.70 | -$2.77 | $3.87 | $38.78 |
| Diluted earnings for the period per share (in euros per share) | -$4.70 | -$2.77 | $3.83 | $37.77 |
| Line item | Dec 31, 2025 · FY | Dec 31, 2024 · FY | Dec 31, 2023 · FY | Dec 31, 2022 · FY |
|---|---|---|---|---|
| Goodwill | $367.9M | $380.6M | $362.5M | — |
| Other intangible assets | $1.6B | $790.4M | $804.1M | $219.7M |
| Property, plant and equipment | $1.1B | $935.3M | $757.2M | $609.2M |
| Right-of-use assets | $210.2M | $248.1M | $214.4M | $211.9M |
| Contract assets | $2.0M | $9.8M | $4.9M | — |
| Other financial assets | $2.6B | $1.3B | $1.2B | $80.2M |
| Other non-financial assets | $7.3M | $26.3M | $83.4M | $6.5M |
| Deferred tax assets | $13.5M | $81.7M | $81.3M | $229.6M |
| Total non-current assets | $5.8B | $3.7B | $3.5B | $1.4B |
| Inventories | $110.7M | $283.3M | $357.7M | $439.6M |
| Trade and other receivables | $924.2M | $1.5B | $2.2B | $7.1B |
| Contract assets | $8.1M | $10.0M | — | — |
| Other financial assets | $7.2B | $7.0B | $4.9B | $189.4M |
| Other non-financial assets | $173.8M | $212.7M | $280.9M | $271.9M |
| Income tax assets | $52.6M | $50.0M | $179.1M | $400.0K |
| Cash and cash equivalents | $7.7B | $9.8B | $11.7B | $13.9B |
| Total current assets | $16.1B | $18.8B | $19.5B | $21.9B |
| Total assets | $22.0B | $22.5B | $23.0B | $23.3B |
| Share capital | $259.0M | $248.6M | $248.6M | $248.6M |
| Capital reserve | $2.5B | $1.4B | $1.2B | $1.8B |
| Treasury shares | -7.7M | -8.6M | -10.8M | -5.3M |
| Retained earnings | $18.0B | $19.1B | $19.8B | $18.8B |
| Other reserves | ($1.5B) | ($1.3B) | ($984.6M) | ($848.9M) |
| Total equity | $19.2B | $19.4B | $20.2B | $20.1B |
| Lease liabilities, loans and borrowings | $215.2M | $214.7M | $191.0M | $176.2M |
| Other financial liabilities | $94.9M | $46.9M | $38.8M | $6.1M |
| Provisions | $35.5M | $20.9M | $8.8M | $8.6M |
| Contract liabilities | $88.0M | $183.0M | $398.5M | $48.4M |
| Other non-financial liabilities | $104.2M | $87.5M | $13.1M | $17.0M |
| Deferred tax liabilities | $84.3M | $42.4M | $39.7M | $6.2M |
| Total non-current liabilities | $622.1M | $595.4M | $689.9M | $272.9M |
| Lease liabilities, loans and borrowings | $52.2M | $39.5M | $28.1M | $36.0M |
| Trade payables and other payables | $534.9M | $426.7M | $354.0M | $204.1M |
| Other financial liabilities | $351.7M | $1.4B | $415.2M | $785.1M |
| Income tax liabilities | $65.6M | $4.5M | $0 | $10.4M |
| Provisions | $145.3M | $144.8M | $269.3M | $367.2M |
| Contract liabilities | $754.9M | $294.9M | $353.3M | $77.1M |
| Other non-financial liabilities | $237.7M | $169.4M | $125.1M | $860.8M |
| Total current liabilities | $2.1B | $2.5B | $2.1B | $3.0B |
| Total liabilities | $2.8B | $3.1B | $2.8B | $3.2B |
| Total equity and liabilities | $22.0B | $22.5B | $23.0B | $23.3B |
| Line item | Dec 31, 2025 · FY | Dec 31, 2024 · FY | Dec 31, 2023 · FY | Dec 31, 2022 · FY |
|---|---|---|---|---|
| Net profit / (loss) | ($1.1B) | ($665.3M) | $930.3M | $9.4B |
| Income taxes | $85.3M | ($12.4M) | $255.8M | $3.5B |
| Profit / (Loss) before tax | ($1.1B) | ($677.7M) | $1.2B | $13.0B |
| Depreciation, amortization and impairment of property, plant, equipment, intangible assets and right-of-use assets | $382.8M | $298.0M | $183.4M | $123.3M |
| Share-based payment expenses | $106.2M | $100.9M | $51.4M | $108.6M |
| Net foreign exchange differences | ($6.6M) | ($109.5M) | ($298.0M) | $625.5M |
| (Gain) / Loss on disposal of property, plant and equipment | ($2.5M) | ($300.0K) | $3.8M | $600.0K |
| Finance income excluding foreign exchange differences | ($423.9M) | ($648.5M) | ($519.6M) | ($265.3M) |
| Finance expense excluding foreign exchange differences | $21.4M | $27.4M | $7.9M | $18.9M |
| Government grants | ($63.0M) | ($31.5M) | $2.4M | $300.0K |
| Other non-cash (income) / loss | $585.4M | — | $0 | $0 |
| Unrealized (gain) / loss on derivative instruments at fair value through profit or loss | ($10.4M) | $4.6M | $175.5M | ($241.0M) |
| Decrease in trade and other receivables, contract assets and other assets | $1.1B | $387.7M | $5.4B | $4.4B |
| Decrease in inventories | $177.9M | $74.5M | $81.9M | $62.9M |
| (Decrease) / Increase in trade payables, other financial liabilities, other liabilities, contract liabilities, refund liabilities and provisions | ($723.8M) | $758.4M | $118.9M | $85.7M |
| Interest received and realized gains from cash and cash equivalents | $337.0M | $474.9M | $258.2M | $29.3M |
| Interest paid and realized losses from cash and cash equivalents | ($11.0M) | ($13.5M) | ($5.4M) | ($21.5M) |
| Income tax received / (paid), net | $3.8M | ($389.2M) | ($482.9M) | ($4.2B) |
| Share-based payments | ($25.3M) | ($154.5M) | ($766.2M) | ($51.8M) |
| Government Grants Received | $75.1M | $106.0M | — | — |
| Net cash flows from operating activities | $456.0M | $207.7M | $5.4B | $13.6B |
| Purchase of property, plant and equipment | ($175.1M) | ($286.5M) | ($249.4M) | ($329.2M) |
| Proceeds from sale of property, plant and equipment | $4.5M | $1.2M | ($700.0K) | $600.0K |
| Purchase of intangible assets | ($573.9M) | ($165.8M) | ($455.4M) | ($34.1M) |
| Acquisition of subsidiaries and businesses, net of cash acquired | $186.3M | $0 | ($336.9M) | $0 |
| Investment in other financial assets | ($11.4B) | ($12.4B) | ($7.1B) | — |
| Proceeds from maturity of other financial assets | $9.5B | $10.7B | $1.2B | $375.2M |
| Net cash flows used in investing activities | ($2.5B) | ($2.1B) | ($7.0B) | ($35.3M) |
| Proceeds from loans and borrowings | $6.7M | $0 | $300.0K | $800.0K |
| Repayment of loans and borrowings | ($18.0M) | ($2.3M) | ($100.0K) | ($18.8M) |
| Payments related to lease liabilities | ($39.6M) | ($43.6M) | ($40.3M) | ($41.1M) |
| Share repurchase program | $0 | $0 | ($738.5M) | ($986.4M) |
| Transaction costs related to issuance of share capital | ($2.0M) | — | — | — |
| Net cash flows used in financing activities | ($52.9M) | ($45.9M) | ($778.6M) | ($1.4B) |
| Net decrease in cash and cash equivalents | ($2.1B) | ($1.9B) | ($2.4B) | $12.1B |
| Change in cash and cash equivalents resulting from exchange rate differences | ($27.0M) | $14.8M | ($14.5M) | $59.6M |
| Change in cash and cash equivalents resulting from other valuation effects | $5.9M | $2.8M | $164.8M | — |
| Cash and cash equivalents at the beginning of the period | $9.8B | $11.7B | $13.9B | $1.7B |
| Cash and cash equivalents as of December 31 | $7.7B | $9.8B | $11.7B | — |
BioNTech SE ADR score and earnings-call analysis · All covered companies
Figures as reported in SEC filings. General information, not investment advice.